Preparation and in vitro–in vivo evaluation of surface-modified poly(lactide-co-glycolide) nanoparticles as controlled release carriers for flutamide delivery

References

• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Del Rev, 2006;58:1688–713
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo S. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Del Rev, 2011;63:170–83
   PubMed Web of Science ®Google Scholar
• Anitha A, Uthaman S, Nair S, Jayakumar R, Lakshmanan V. Enhanced delivery system of flutamide loaded chitosan-dextran sulphate nanoparticles for prostate cancer. J Biomed Nanotechnol, 2012;9:1–13
   Web of Science ®Google Scholar
• Cho HS, Dong Z, Pauletti GM, Zhang J, Xu H, Gu H, Wang L, Ewing RC, Huth C, Wang F, Shi D. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: A multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano, 2010;4:5398–404
   PubMed Web of Science ®Google Scholar
• Chorny M, Fishbein I, Danenberg H, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetic. J Control Release, 2002;83:389–400
   PubMed Web of Science ®Google Scholar
• Cruz L, Tacken P, Fokkink R, Figdor C. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials, 2011;32:6791–803
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva J, Coco R. PLGA-based nanoparticles: An overview of biomedical applications. J Cont Release, 2012;161:505–22
   PubMed Web of Science ®Google Scholar
• Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Biopolymeric microparticles combined with lyophilized monophase dispersions for controlled flutamide releas. Int J Pharm, 2011;411:113–19
   PubMed Web of Science ®Google Scholar
• Elzoghby A, Helmy M, Samy W. Spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: Formulation, characterization, and in vivo pharmacokinetics. Eur J Pharm Biopharm, 2013;84(3):487–96
   PubMed Web of Science ®Google Scholar
• Fizazi K, Navone NM. Preclinical models of prostate cancer. Bull Cancer 2005;92:129–41
   PubMed Web of Science ®Google Scholar
• Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly (lactide-co-glycolic acid) based drug delivery systems – A review. Int J Pharm, 2011;415:34–52
   PubMed Web of Science ®Google Scholar
• Gref R, Domb A, Quellec P, Blunk T, Müller R, Verbavatz J. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev, 2012;64:316–26
   Web of Science ®Google Scholar
• Gronberg H. Prostate cancer epidemiology. Lancet, 2003;361:859–64
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 1997;86:1–12
   PubMed Web of Science ®Google Scholar
• Heffery J, Davis SS, O’Hagan DT. The preparation and characterization of poly (lactide-co-glycolide) microparticles. I. Oil-in-water emulsion solvent evaporation. Int J Pharm, 1991;77:169–75
   Google Scholar
• Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT Corepressors. Cancer Res, 2007;67:8388–95
   PubMed Web of Science ®Google Scholar
• Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B Biointerfaces, 2013;108:366–73
   PubMed Web of Science ®Google Scholar
• Jain V, Swarnakar N, Mishra P, Verma A, Kaul A, Jain N. Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy. Biomaterials, 2012;33:7206–20
   PubMed Web of Science ®Google Scholar
• Jinping W, Xiangyuan Y, Delin L, Duan L. Bioavailability and pharmacokinetics of flutamide tablets studied by determination of its active metabolites in serum in Chinese subjects. J Chinese Pharm Sci, 1999;8(3):181–4
   Google Scholar
• Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm, 2006;62:3–16
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Multidrug resistance in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 2000;11:265–83
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav S, Yadav S. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 2010;75:1–18
   PubMed Web of Science ®Google Scholar
• Laverman P, Carstens MG, Moghimi SM. Recognition and clearance of methoxy poly(ethylene glycol) 2000-grafted liposomes by macrophages with enhanced capacity: Implications in experimental and clinical oncology. Biochem Biophys Acta, 2001;1523:227–9
   Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev, 2001;53:283–318
   PubMed Web of Science ®Google Scholar
• Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto SB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles versus drug nanocrystals. Int J Pharm, 2006;317:82–9
   PubMed Web of Science ®Google Scholar
• Müller RH, Keck CM. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur J Pharm Biopharm, 2012;80:1–3
   PubMed Web of Science ®Google Scholar
• Nesalin J, Gowthamarajan K, Somashekhara C. Formulation and evaluation of nanoparticles containing flutamide. Int J Chem Tech Res, 2009;1:1331–4
   Google Scholar
• Niopas I, Daftsios A. Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chrom B, 2001;759:179–83
   PubMed Web of Science ®Google Scholar
• Okamoto R, Delansoren R, Wakimoto N, Doan NB, Akagi T, Shen M, Ho QC, Said JW, Koeffer HP. Inecalcitol, an analog of 1α, 25(OH)2 D3, induced growth arrest of androgen dependent prostate cancer cells. Int J Cancer, 2012;130:2464–73
   PubMed Web of Science ®Google Scholar
• Owens D, Peppas N. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticle. Int J Pharm, 2006;307:93–102
   PubMed Web of Science ®Google Scholar
• Palumbo P, Andrea P, Daniela T, Pasquale P. Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of flutamide. J Drug Target, 2012;20:433–41
   PubMed Web of Science ®Google Scholar
• Pamujula S, Hazari S, Bolden G, Graves R, Chinta A, Dash S. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol, 2012;64(1):61–7
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev, 2003;55:339–47
   Google Scholar
• Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol, 2011;670:372–83
   PubMed Web of Science ®Google Scholar
• Sah H, Thoma LA, Desu HR, Sah E, Wood GL. Concept and practices used to develop functional PLGA based nanoparticulate systems. Int J Nanomed, 2013;8:747–65
   PubMed Web of Science ®Google Scholar
• Sahoo NG, Abbas A, Li CM. Micro/nanoparticle design and fabrication for pharmaceutical drug preparation and delivery applications. Curr Drug Ther, 2008;3:78–97
   Google Scholar
• Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B, Singh J. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection. J Control Release, 2013;167:1–10
   PubMed Web of Science ®Google Scholar
• Sternal R, Nugara N. 2001. Flutamide. In: Brittain HG, ed. Analytical profiles of drug substances and excipents, vol. 27. San Diego: Academic Press, pp. 118–57
   Google Scholar
• Svenson S. 2004. Overview: Carrier-based drug delivery. In: Svenson S, ed. Carrier-based drug delivery. ACS Symposium Series 879. Washington, DC: American Chemical Society, pp. 2–23
   Google Scholar
• Zuo Z, Tam Y, Diakur J, Wiebe L. Hydroxypropyl-B-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci, 2002;5(3):292–8
   PubMed Web of Science ®Google Scholar